Role of Genetic Testing in Advanced M1 CRPC & M1 CPRC Post-docetaxel, Neuroendocrine Cancer and End of Life Care

Presented by Leonard Gomella, MD and Joshua Lang, MD

https://auau.auanet.org/node/34071

Acknowledgements

Support provided by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Exact Sciences Corporation

Merck

Pfizer, Inc.

Sanofi Genzyme

Optimizing the Treatment of Complicated UTIs

CME Available: https://auau.auanet.org/node/33500

ACKNOWLEDGEMENT:

This activity is supported by an independent educational grant from Spero Therapeutics.

Early M1 CRPC & Advanced M1 CRPC

Presented by Kelly Stratton, MD and Deborah Kaye, MD

CME Available: https://auau.auanet.org/node/34065

Acknowledgements

Support provided by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Exact Sciences Corporation

Merck

Pfizer, Inc.

Sanofi Genzyme

Advances in Immuno-Oncology in Urothelial Carcinoma Podcast (2021)

CME Available: https://auau.auanet.org/node/33484

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Lantheus Medical Imaging

Merck

Pfizer, Inc.

BCR and Novel Pet Imaging & M0 CRPC

Presented by Stephen Boorjian, MD and Michael Cookson, MD

CME Available: https://auau.auanet.org/node/34059

Acknowledgements

Support provided by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Exact Sciences Corporation

Merck

Pfizer, Inc.

Sanofi Genzyme

This podcast was funded by and developed in collaboration with Boston Scientific

CME Available: https://auau.auanet.org/node/33094

Acknowledgements

This educational activity is supported by an independent educational grant from:

Urovant

CME Available: https://auau.auanet.org/node/33093

At the conclusion of the activity, participants will be able to:

1. Describe recent developments in the medical management of advanced prostate cancer.

2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.

3. Discuss clinical investigations in the treatment of advanced prostate cancer.

4. Analyze the risks and benefits of treatment for advanced prostate cancer.

5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.

Acknowledgements

This educational activity is supported by independent educational grants from Astellas, AstraZeneca, Merck, Pfizer, Inc.

NMIBC Guidelines by American Urological Association

Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc.

CME Available: auau.auanet.org/node/31819

At the conclusion of this educational series, participants will be able to:

1. Discuss the impact of SDM on patients and on patient-clinician communication.

2. Identify at least one implementation strategy for using SDM in clinical practice.

3. Apply SDM techniques in a role-playing exercise with other colleagues.

4. Incorporate culturally sensitive communications to ensure quality SDM and reduce biases.

5. Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.